StockNews.com Upgrades uniQure (NASDAQ:QURE) to Sell

uniQure (NASDAQ:QURE) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a report issued on Tuesday.

A number of other research analysts also recently weighed in on the stock. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and raised their price target for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of uniQure in a report on Tuesday, March 4th. Wells Fargo & Company cut their price target on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a report on Friday, February 28th. The Goldman Sachs Group raised their price target on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 12th. Finally, Leerink Partners raised their price target on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $38.89.

uniQure Stock Up 6.8 %

QURE stock traded up $0.80 during midday trading on Tuesday, reaching $12.50. The company had a trading volume of 773,396 shares, compared to its average volume of 1,023,609. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a market capitalization of $675.96 million, a P/E ratio of -2.52 and a beta of 0.36. The company has a 50 day moving average of $14.27 and a two-hundred day moving average of $10.09.

Insiders Place Their Bets

In other news, CFO Christian Klemt sold 14,341 shares of the firm’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the completion of the transaction, the chief financial officer now directly owns 152,372 shares of the company’s stock, valued at approximately $1,630,380.40. This trade represents a 8.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Matthew C. Kapusta sold 6,717 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $76,036.44. Following the transaction, the chief executive officer now directly owns 580,795 shares of the company’s stock, valued at $6,574,599.40. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 90,830 shares of company stock worth $961,401 in the last ninety days. Insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On uniQure

A number of hedge funds and other institutional investors have recently made changes to their positions in QURE. China Universal Asset Management Co. Ltd. lifted its holdings in uniQure by 9.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 969 shares during the last quarter. Tudor Investment Corp ET AL boosted its holdings in shares of uniQure by 5.9% in the fourth quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company’s stock valued at $438,000 after buying an additional 1,371 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of uniQure by 13.9% in the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock valued at $217,000 after buying an additional 1,503 shares during the period. Northern Trust Corp boosted its holdings in shares of uniQure by 2.1% in the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock valued at $1,688,000 after buying an additional 1,923 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of uniQure by 6.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company’s stock valued at $1,253,000 after buying an additional 3,996 shares during the period. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.